Catalent Inc (NYSE:CTLT) has been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $44.29.
A number of brokerages have recently commented on CTLT. Needham & Company LLC began coverage on Catalent in a report on Tuesday, September 12th. They set a “hold” rating and a $42.00 price objective on the stock. Zacks Investment Research lowered Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Bank of America restated a “buy” rating and set a $40.00 target price (up previously from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $45.00 target price on shares of Catalent in a research note on Tuesday, August 29th.
Shares of Catalent (NYSE:CTLT) traded down $0.01 during midday trading on Thursday, hitting $41.94. The stock had a trading volume of 775,800 shares, compared to its average volume of 918,273. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The firm has a market cap of $5,573.46, a price-to-earnings ratio of 29.34, a price-to-earnings-growth ratio of 2.70 and a beta of 1.41. Catalent has a fifty-two week low of $25.51 and a fifty-two week high of $43.39.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Catalent by 15.2% during the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the period. Vanguard Group Inc. lifted its position in shares of Catalent by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock worth $355,192,000 after buying an additional 369,526 shares during the period. Janus Henderson Group PLC bought a new position in shares of Catalent during the 2nd quarter worth approximately $239,629,000. JPMorgan Chase & Co. lifted its position in shares of Catalent by 4.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock worth $180,403,000 after buying an additional 226,705 shares during the period. Finally, State Street Corp lifted its position in shares of Catalent by 10.7% during the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after buying an additional 418,196 shares during the period. Institutional investors own 99.37% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.